Serological responses and six-month trajectories to COVID-19 Comirnaty and Spikevax booster vaccine, September 2021 to January 2022, London, United Kingdom
Ireland, G.; Whitaker, H.; Ladhani, S.; Baawuah, F.; Subbarao, S.; Elgohari, S.; Smith, A.; O'Brien, M.; Whillock, C.; Martin, O.; Moss, P.; Ramsay, M. E.; Amirthalingam, G.; Brown, K. E.
Show abstract
In contrast to the increasing levels of high avidity S antibody measured by the Roche assay in the first 6 months following natural infection, marked waning is seen post 2 or 3 doses of vaccine. Although the kinetics differ between those with vaccine-induced immunity compared to those infected prior to vaccination (hybrid immunity), waning rates appear to be similar following 2 or 3 doses of vaccine. These data should allow countries to optimise the timing of future doses of vaccine.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study 97%
- Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial 97%
- Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection 96%
Similar papers in this journal
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 95%
- Initial protection against Omicron in children and adolescents by BNT162b2 95%
- Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong 95%
Similar papers in this journal
- Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England 97%
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 97%
- Effect of booster vaccination against Delta and Omicron variants in Iceland 96%
Similar papers in this journal
- Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial 95%
- Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults 93%
- Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: a randomised, double-blind, non-inferiority trial 93%
Similar papers in this journal
- Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study 95%
- BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar 95%
- Predicting the efficacy of variant-modified COVID-19 vaccine boosters 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.